| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/17/2011 | EP2356109A2 Compositions and methods for treating alcohol use disorders, pain and other diseases |
| 08/17/2011 | EP2356093A1 Carbazole compounds and therapeutic uses of the compounds |
| 08/17/2011 | EP2356091A2 Substituted amido phenoxybenzamides |
| 08/17/2011 | EP2355850A2 N-cadherin: target for cancer diagnosis and therapy |
| 08/17/2011 | EP2355848A2 Blockers of light, ltalpha1beta2 and ltalpha2beta1 or their receptor ltbetar for the prevention and treatment of chronic hepatitis and other liver diseases |
| 08/17/2011 | EP2355847A1 Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
| 08/17/2011 | EP2355833A2 Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells |
| 08/17/2011 | EP2355831A1 Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer |
| 08/17/2011 | EP2355828A1 Therapies for hematologic malignancies |
| 08/17/2011 | EP2355821A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy |
| 08/17/2011 | EP2355820A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| 08/17/2011 | EP2355819A2 Treating cancer by modulating a mnk |
| 08/17/2011 | EP2355810A2 Methods for preventing or reducing carcinogenesis or oxidative stress |
| 08/17/2011 | EP2355809A1 Methods for preventing or reducing colon carcinogenesis |
| 08/17/2011 | EP2355807A1 Inhibitors of dimethylarginine dimethylaminohydrolase |
| 08/17/2011 | EP2355797A1 Composition for targeting dendritic cells |
| 08/17/2011 | EP2190836B1 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| 08/17/2011 | EP2091919B1 Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer |
| 08/17/2011 | EP1922087B1 Method for the preparation of polymeric conjugates of doxorubicin with ph-controlled release of the drug |
| 08/17/2011 | EP1915151B1 Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors |
| 08/17/2011 | EP1896422B1 Tyrosine kinase inhibitors |
| 08/17/2011 | EP1885717B1 Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
| 08/17/2011 | EP1761505B1 Pyrimidine urea derivatives as kinase inhibitors |
| 08/17/2011 | EP1638509B1 Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| 08/17/2011 | EP1511713B1 Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| 08/17/2011 | EP1507558B1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 08/17/2011 | EP1491553B1 Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumours |
| 08/17/2011 | EP1444233B1 A2b adenosine receptor antagonists |
| 08/17/2011 | EP1404841B1 Cyp1b1 nucleic acids and methods of use |
| 08/17/2011 | EP1402253B1 A process for the isolation of a major harmful oxidant from cigarette smoke |
| 08/17/2011 | EP1379507B1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 08/17/2011 | EP1327003B1 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 08/17/2011 | EP1272619B1 Human ovarian mesothelial cells and methods of isolation and uses thereof |
| 08/17/2011 | EP1246808B1 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 08/17/2011 | CN1924014B Interference RNA sequence of specificity interference MTA1 mRNA for inhibiting tumor metastasis |
| 08/17/2011 | CN1907989B Setoglaucine salt, preparation method thereof and medicinal composition containing the same |
| 08/17/2011 | CN1898232B Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
| 08/17/2011 | CN1549717B Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity, and pharmaceutical uses |
| 08/17/2011 | CN102159582A Oxazolopyrimidines as edg-1 receptor agonists |
| 08/17/2011 | CN102159577A Imidazo[1,2-a]pyrimidine derivatives, method for preparation thereof, use thereof as medicaments, pharmaceutical compositions and met inhibitors |
| 08/17/2011 | CN102159574A Tri-cyclic pyrazolopyridine kinase inhibitors |
| 08/17/2011 | CN102159573A Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 08/17/2011 | CN102159569A Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT |
| 08/17/2011 | CN102159568A 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors |
| 08/17/2011 | CN102159566A Pyridone and pyridazone analogues as gpr119 modulators |
| 08/17/2011 | CN102159559A Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 08/17/2011 | CN102159555A Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| 08/17/2011 | CN102159543A Novel triazolo(4,3-a)pyridine derivatives, process for preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 08/17/2011 | CN102159541A Anticancer oral formulation |
| 08/17/2011 | CN102159250A Multi-arm polymeric alkanoate conjugates |
| 08/17/2011 | CN102159248A Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 08/17/2011 | CN102159241A Tapasin augmentation for enhanced immune response |
| 08/17/2011 | CN102159239A Vaccine against HPV |
| 08/17/2011 | CN102159222A Bioactive agent,pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent |
| 08/17/2011 | CN102159214A Inhibitors of bruton's tyrosine kinase for treatment of solid tumors |
| 08/17/2011 | CN102159212A Use of opioids or opioid mimetics for treatment of resistant cancer patients |
| 08/17/2011 | CN102159207A Substituted pyrrolidine-2-carboxamides |
| 08/17/2011 | CN102159192A Preparation method of biodegradable micro-particles containing drugs |
| 08/17/2011 | CN102154482A Application of calcium activated chloride channels ANO1/TMEM16A in diagnosis and treatment of prostate cancer |
| 08/17/2011 | CN102154368A Tissue specificity and regulation lentivirus gene expression vector |
| 08/17/2011 | CN102154355A Recombinant immunotoxin CCL25-PE38 gene and preparation method as well as application thereof |
| 08/17/2011 | CN102154325A Vaccine against human papillomavirus (HPV) as well as preparation method and application thereof |
| 08/17/2011 | CN102154292A siRNA fragment of c-Met gene and application thereof |
| 08/17/2011 | CN102154223A Recombinant adenovirus with fusion protein gene and preparation method and application thereof |
| 08/17/2011 | CN102154218A Hybridoma cell strain 4e9 and monoclonal antibody produced by using hybridoma cell strain 4e9 |
| 08/17/2011 | CN102154208A Preparation method and use of cord blood-derived (CD)133 and brain glioma stem cell antigen carrying dendritic cells |
| 08/17/2011 | CN102154206A Preparation method of high-purity, high-multiplication capacity and high-cytotoxin activity CIK (cytokine induced kill) cell |
| 08/17/2011 | CN102154205A Method for preparing high-purity and high-cytotoxin-activity gamma delta T cells |
| 08/17/2011 | CN102153668A Anticancer Armillaria luteovirens polysaccharide and extraction process thereof |
| 08/17/2011 | CN102153658A Tumor antigen, DC (dendritic cell) tumor vaccine and preparation method thereof |
| 08/17/2011 | CN102153657A IL-24-TAT PTD fusion protein and construction method and application thereof |
| 08/17/2011 | CN102153655A Targeted anti-tumor recombinant protein and preparation method thereof |
| 08/17/2011 | CN102153653A Fusion protein of tumor blood vessel targeted polypeptide and tissue factor and preparation method thereof |
| 08/17/2011 | CN102153650A Anti-EGFR (epidemic growth factor receptor) humanized antibody L2-H3 and coding gene and application thereof |
| 08/17/2011 | CN102153649A Anti-epidemic growth factor receptor (EGFR) humanized antibody L1-H3 and coded gene and application thereof |
| 08/17/2011 | CN102153648A EGFR (epidermal growth factor receptor)-inhibiting humanized antibody L4-H3 and encoding genes and application thereof |
| 08/17/2011 | CN102153647A Anti-EGFR (epidemic growth factor receptor) humanized antibody L3-H3 and coding gene and application thereof |
| 08/17/2011 | CN102153644A Antigenic peptide for dimerization of epidermal growth factor receptor |
| 08/17/2011 | CN102153627A Modifier for gelatinase A inhibitory polypeptide and preparation method thereof |
| 08/17/2011 | CN102153610A Nitric oxide donor type bile acid derivatives as well as preparation methods and medicinal application thereof |
| 08/17/2011 | CN102153607A Water soluble camptothecin derivative and medicinal composition containing same |
| 08/17/2011 | CN102153606A Nucleoside derivatives as well as stereo isomers, pharmaceutically acceptable salts and application thereof |
| 08/17/2011 | CN102153577A 2-seleno-N-pyridine oxide-rare earth metal ion compound and preparation method and application thereof |
| 08/17/2011 | CN102153564A Nitrogen-atom-containing arteannuin dimers, and preparation method and application thereof |
| 08/17/2011 | CN102153558A Derivative of multi-target antitumor inhibitor 2-aminopyrrole-triazine and synthesis method thereof |
| 08/17/2011 | CN102153551A Indazole/azaindazole-based diarylcarbamide/thiocarbamide-structure antineoplastic drug |
| 08/17/2011 | CN102153549A Gamma carboline compound as well as preparation method and application thereof |
| 08/17/2011 | CN102153544A Preparation method and application of novel tyrosine kinase inhibitors |
| 08/17/2011 | CN102153543A Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
| 08/17/2011 | CN102153540A Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 08/17/2011 | CN102153538A Benzocyclodirivative |
| 08/17/2011 | CN102153535A Benzopyranyl-3-alcohol esterified derivative serving as antineoplastic multidrug resistance inhibitor and preparation method and application of benzopyranyl-3-alcohol esterified derivative |
| 08/17/2011 | CN102153534A Compound with tyrosinase inhibitory activity as well as preparation method and application thereof |
| 08/17/2011 | CN102153529A Single-tetrahydrofuran-type annonaceous acetogenin compounds with antitumor activity and application thereof |
| 08/17/2011 | CN102153517A Diaryl pyrimidone hydrazone derivatives and preparation method and application of diaryl pyrimidone hydrazone derivatives |
| 08/17/2011 | CN102153515A N,N'-bis-substituted urea Raf kinase inhibitors and preparation method and application thereof |
| 08/17/2011 | CN102153508A 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs |
| 08/17/2011 | CN102153498A Resveratrol analogue and preparation method and application thereof |
| 08/17/2011 | CN102153492A Treatment medicament for resisting infectious diseases, and preparation method and application thereof |
| 08/17/2011 | CN102153488A Alpha,beta-diamino acid derivative, synthetic method thereof and application thereof |